Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Withdrawn 1Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 2Oligodendroglioma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Astrocytoma 1Advanced Breast Cancer 1

Interventions

Carboplatin 84Cisplatin 79Pemetrexed 72Docetaxel 62Drug Therapy 44Gemcitabine 43Erlotinib Hydrochloride 42Gefitinib 38Radiotherapy 36Paclitaxel 36pembrolizumab 31Bevacizumab 29icotinib 28osimertinib 27anlotinib 26Nivolumab 26camrelizumab 23Vinorelbine 23Radiosurgery 20aumolertinib 18atezolizumab 17sintilimab 16apatinib 16Endostatins 16endostar protein 15durvalumab 14Surgical Procedures, Operative 13Immunotherapy 13Immune Checkpoint Inhibitors 12Blood Specimen Collection 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Non-Small-Cell Lung × In Situ Hybridization, Fluorescence × Clear all
NCT00989690 2013-08-12

Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
275 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡